172 related articles for article (PubMed ID: 27822042)
1. Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder.
Huang Q; Zhong X; Yun Y; Yu B; Huang Y
Neuropsychiatr Dis Treat; 2016; 12():2707-2714. PubMed ID: 27822042
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.
Gommoll CP; Greenberg WM; Chen C
J Drug Assess; 2014; 3(1):10-9. PubMed ID: 27536449
[TBL] [Abstract][Full Text] [Related]
3. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
5. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
6. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
[TBL] [Abstract][Full Text] [Related]
7. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study.
Durgam S; Chen C; Migliore R; Prakash C; Thase ME
Depress Anxiety; 2019 Mar; 36(3):225-234. PubMed ID: 30675739
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.
Shiovitz T; Greenberg WM; Chen C; Forero G; Gommoll CP
Innov Clin Neurosci; 2014 Jan; 11(1-2):10-22. PubMed ID: 24653937
[TBL] [Abstract][Full Text] [Related]
10. The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.
Kornstein SG; Gommoll C; Chen C; Kramer K
J Affect Disord; 2016 Mar; 193():137-43. PubMed ID: 26773906
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.
Montgomery SA; Mansuy L; Ruth AC; Li D; Gommoll C
Int Clin Psychopharmacol; 2014 Jan; 29(1):26-35. PubMed ID: 24172160
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.
Montgomery SA; Gommoll CP; Chen C; Greenberg WM
CNS Spectr; 2015 Apr; 20(2):148-56. PubMed ID: 24902007
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
McIntyre RS; Gommoll C; Chen C; Ruth A
CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
[TBL] [Abstract][Full Text] [Related]
14. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
Bruno A; Morabito P; Spina E; Muscatello MR
Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
Blum SI; Tourkodimitris S; Ruth A
J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
[TBL] [Abstract][Full Text] [Related]
16. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
Scott LJ
CNS Drugs; 2014 Nov; 28(11):1071-82. PubMed ID: 25270036
[TBL] [Abstract][Full Text] [Related]
17. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.
Maneeton N; Maneeton B; Srisurapanont M; Martin SD
BMC Psychiatry; 2012 Sep; 12():160. PubMed ID: 23017200
[TBL] [Abstract][Full Text] [Related]
18. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.
Freeman MP; Fava M; Gommoll C; Chen C; Greenberg WM; Ruth A
Int Clin Psychopharmacol; 2016 Mar; 31(2):100-9. PubMed ID: 26584326
[TBL] [Abstract][Full Text] [Related]
19. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.
Blier P; Gommoll C; Chen C; Kramer K
J Affect Disord; 2017 Mar; 210():273-279. PubMed ID: 28068615
[TBL] [Abstract][Full Text] [Related]
20. Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study.
Wesnes KA; Gommoll C; Chen C; Sambunaris A; McIntyre RS; Harvey PD
Int Clin Psychopharmacol; 2017 Mar; 32(2):72-79. PubMed ID: 27861191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
